Magnera Corp (MAGN) stock intrinsic value fair value estimate & owner earnings analysis

Magnera makes nonwoven fabrics: the soft spunbond and meltblown materials inside diapers, feminine-care and adult-incontinence products, wipes, medical gowns and filters, plus the airlaid and wetlaid specialty materials that came from Glatfelter (tea and coffee filter papers, wallcover base, tabletop and electrical materials). It was formed on November 4, 2024 when Berry Global spun off its Health, Hygiene & Specialties nonwovens business and merged it with Glatfelter. The Berry business is the accounting predecessor, so financial history before the merger describes the Berry carve-out alone, not today's combined company. Sales in the nine months to June 2026 were $2.45 billion, about 55% in the Americas and 45% in the rest of the world, sold largely to a small number of big consumer-products and medical customers. It is a commodity-like, capital-heavy business that competes on cost and reliability. How we measured earnings. We start from operating cash flow, strip out working-capital swings, and charge stock compensation and capital spending as real costs. The Berry carve-out produced $105 million of owner earnings in fiscal 2023 and $114 million in fiscal 2024. The first combined year, fiscal 2025, produced only $25 million after $124 million of cash interest on the merger debt and heavy integration costs ($89 million of restructuring charges). Because the company carries about $1.97 billion of debt, we value the business before its lenders: adding back cash interest, fiscal 2025 cash flow before debt was about $149 million. In the nine months to June 2026 that figure rose to about $162 million from $152 million a year earlier, as merger cost savings came through and volumes edged up 1%; three straight quarters of improvement support a starting level of about $155 million a year (roughly $4.30 a share on 35.9 million diluted shares). Only fiscal 2025 onward reflects the business as it exists now, so that is our window. Accounting judgments: amortization of acquired customer relationships (about $45-50 million a year) and the $171 million fiscal 2024 goodwill write-down are non-cash and added back; their economic decay is carried by holding earnings flat in dollars (falling in real terms) rather than growing them. Capital spending ($67 million in fiscal 2025, about $60 million expected for 2026) runs well under half of depreciation (about $155 million a year), which we judge unsustainable over a decade, so every case raises capital spending over time. Growth. Year-one cash flow in the base case is about $150 million, roughly 1% above fiscal 2025 and below the 7% year-on-year improvement seen in the latest nine months. We credit no market growth, share gains or pricing gains: the Berry business's sales fell 4% in fiscal 2024 and the hygiene market faces customer pricing pressure and overcapacity. Management's further 'Project CORE' savings target is not credited in the base case because it has not yet been delivered. Base case ($4.92 a share): cash flow before debt of about $150 million in year one; elevated restructuring cash costs fade back to the roughly $25-30 million a year the Berry business historically spent once Project CORE ends (about +$15 million from 2029); capital spending climbs about $25 million a year toward a sustainable level by 2031; earnings then hold at about $145 million through year 25 before fading to zero over the following 15 years as the plant base ages. Cash flow in this case only just covers the roughly $140 million annual interest bill, so little debt gets repaid and the 2029 and 2031 maturities must be refinanced on terms similar to today's. Discounted at 6%, the business is worth about $2.05 billion. It owes $1.97 billion face value of debt ($706 million term loan due November 2031 at SOFR plus 4.25%, $760 million of 7.25% notes due November 2031, and $500 million of 4.75% notes due October 2029). The term loan and 7.25% notes cost more than 6% until they mature, adding about $100 million in present value, while the cheap 4.75% notes save about $17 million; netting about $180 million of cash beyond operating needs, net debt is about $1.87 billion. Business value minus debt leaves about $177 million for shareholders. The equity is a thin slice of a large enterprise: every $5 million a year of lasting cash flow moves the value by roughly $2 a share. Bear case (-$28.51 a share): price pressure from concentrated hygiene customers continues at the pace the Berry business already showed (cash flow starting near $140 million and slipping 1.5% a year), restructuring costs stay elevated, capital spending must rise about $40 million a year to keep aging lines running, and earnings fade to zero over the decade after year 20. The business would be worth about $1.12 billion. Because cash flow in this case falls below the roughly $140 million annual interest bill within a few years, the 2029 and 2031 maturities would have to be refinanced at stressed rates near 9%, lifting what it effectively owes to about $2.15 billion. The company would owe roughly $1.0 billion more than it is worth, which in practice means a debt restructuring leaving shareholders little or nothing. Bull case ($27.99 a share): the merger savings and Project CORE program, already under way and paid for through current restructuring charges, deliver their identified cost cuts (about +$40 million a year from 2029 including the end of elevated restructuring spending), the recent 1% volume gains hold, and capital spending needs only modest increases. Cash flow before debt reaches about $200 million and holds through year 30 before fading to zero over the following 15 years. The business would be worth about $2.88 billion against $1.87 billion of net debt, leaving about $1.0 billion for shareholders. Testing the case. We checked the interest add-back against the filings (2025 interest expense of $141 million less $17 million non-cash equals the $124 million cash interest the company reports) and confirmed no debt matures before October 2029 and the loans carry no financial maintenance covenants. The biggest risk to the base case is the gap between capital spending and depreciation: if the plants need much more reinvestment than we assume, the equity value disappears. What would have to be true for the base case to be wrong on the upside is real, lasting delivery of the Project CORE savings. Change since our previous analysis: our base value rises from $3.35 to $4.92 because nine months of fiscal 2026 showed cash generation improving as merger savings arrived; our bull value falls from $34.70 to $27.99 because we no longer assume growth beyond identified cost savings; and our bear case now shows the shares worth less than nothing rather than near zero, because we now value the business before debt at a single 6% rate and charge the risk of refinancing $1.97 billion of debt directly in the downside case.